Following U.S. and Japan, Oncosoft enters Singapore market, signing a multi-year supply agreement for AI-based radiation therapy software 'OncoStudio'
Medical AI company Oncosoft announced on the 21st that it has signed a multi-year supply agreement for its research software 'OncoStudio' with Proton Therapy SG, a specialized cancer treatment center in Singapore.
Proton Therapy SG is a medical institution equipped with advanced radiation therapy technologies such as proton therapy and stereotactic ablative body radiotherapy (SABR), providing patient-centered, high-precision cancer treatment services.
According to Oncosoft, the agreement follows months of careful comparison and review of global competitive products by the institution, which highly praised OncoStudio's accuracy, user-friendliness, and clinical applicability.
OncoStudio is a software that uses artificial intelligence to perform auto-contouring, a key step in radiation therapy planning. It is equipped with algorithms that can be precisely applied to various anatomical regions, and Proton Therapy SG plans to actively utilize the solution in its clinical research.
This agreement is a multi-year, subscription-based supply contract, not a one-time delivery. Oncosoft will provide stable technical support for Proton Therapy SG's research environment while also proceeding with the medical device approval process with Singapore's Health Sciences Authority (HSA).
Following its recent supply agreement with the Mayo Clinic in the U.S., as well as obtaining U.S. FDA and Japanese medical device certifications, Oncosoft is now accelerating its global market expansion by entering the Singapore market.
An Oncosoft official stated, "This contract signifies that our technology is gaining trust in the international market." The official added, "We will continue to expand cooperation with global partners to continue innovative technological exchange in the field of cancer treatment."
